Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000062527
Ethics application status
Approved
Date submitted
13/12/2023
Date registered
25/01/2024
Date last updated
8/09/2026
Date data sharing statement initially provided
25/01/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Evaluate the effectiveness of the SAFE-T nursing care bundle in protecting skin from DEvice harm across the liFEspan iN Critical illnEss: The DEFENCE project
Query!
Scientific title
A hybrid type 2 effectiveness-implementation study with a sequential, multi-centre, incomplete stepped wedge cluster trial to evaluate the effectiveness of the SAFE-T nursing care bundle to prevent device related pressure injuries in ICU patients across the lifespan
Query!
Additional trial identifiers [1]
310836
0
Grant ID: APP2022546: Issuing authority: Australian Government (NH&MRC Partnership Scheme)
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
DEFENCE
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Device-related pressure injuries
332293
0
Query!
Condition category
Condition code
Skin
329007
329007
0
0
Query!
Other skin conditions
Query!
Injuries and Accidents
329008
329008
0
0
Query!
Other injuries and accidents
Query!
Public Health
329205
329205
0
0
Query!
Health service research
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
The SAFE-T Bundle is an evidence-based nursing care bundle comprising five elements to prevent medical device-related pressure injuries in critically ill patients. The SAFE-T Bundle provides guidance to ICU clinicians regarding selection and sizing of devices, assessment and protection of skin, device fixation and securement, repositioning of devices, and timely device removal. Site-specific implementation strategies, including education and training, will be developed through the Phase 1 implementation survey, workshops and site implementation meetings. The bundle elements remain consistent across sites but are tailored to the devices used, patient population and clinical practices at each ICU.
The SAFE-T Bundle consists of five elements:
1. Select and size the device: Device application should be based on direct clinical need, and devices should be appropriately sized and fitted to the patient.
2. Assess and protect the skin: The condition of the skin and mucous membranes under and around the device, including associated tubing and cords, should be assessed regularly as part of routine skin assessment (minimum 8-hourly). Appropriate measures should be used to protect areas at risk of pressure-related tissue damage.
3. Fix and secure the device: Devices should be fixed and secured to maintain patency and performance while minimising mechanical pressure and shear forces at the device-skin or device-tissue interface. Where appropriate, devices should be kept free within an orifice rather than creating pressure against surrounding tissues.
4. Evaluate and exchange the position of the device: Devices should be repositioned or rotated where possible to redistribute or offload pressure over different parts of the tissues, optimally at least 4-hourly where appropriate and depending on device type. Care should be taken to minimise gravitational pull of the device on the skin and other tissues.
5. Timely removal of devices: Removal of, or changing the location of, devices should be considered regularly (at least daily), with devices removed as soon as clinically possible.
The bundle applies to a broad range of medical devices, including devices used for breathing (endotracheal tubes, bite blocks, high-flow nasal prongs, face masks, nasal cannulae, CPAP and tracheostomy); feeding (nasogastric and orogastric tubes, PEG and jejunostomy); vascular access and other catheters (central lines, arterial lines, PICCs, ECMO, dialysis and peripheral intravenous catheters); monitoring probes (oxygen saturation probes, blood pressure cuffs, ECG dots and leads, temperature and glucose monitors, intracranial pressure monitoring probes and tubes); indwelling and suprapubic catheters; restraints and braces; bowel management systems; and other devices including DVT prophylaxis devices, epidurals, and cooling and warming blankets.
The SAFE-T Bundle will be delivered by ICU nursing staff as part of routine patient care. Site investigators and study champions will provide training, education and assistance to ICU clinicians during implementation. The implementation strategies will be informed by the Phase 1 implementation survey and workshops and further adapted through implementation meetings at each participating ICU.
The SAFE-T Bundle will be incorporated into routine nursing care at the bedside. Site investigators and study champions will support implementation through education, training, liaison with ICU clinicians and assistance with implementation of the five bundle elements. The implementation approach will be adapted to each ICU according to local barriers and enablers, devices used, patient population and existing clinical practices, while the five SAFE-T Bundle elements remain unchanged.
The SAFE-T Bundle will be introduced during a two-month transition period. The bundle will then be delivered as part of routine nursing care throughout the six-month intervention period. The bundle will subsequently be assessed during a one-month sustainability period following a three-month wash-out period. The individual bundle activities are incorporated into routine care at clinically appropriate intervals: skin assessment at a minimum of 8-hourly, repositioning or exchange of device position optimally at least 4-hourly where appropriate and device removal or relocation considered at least daily.
The intervention will be delivered in eight ICUs across five public hospitals in Queensland, comprising neonatal, paediatric and adult ICU settings. The participating ICUs are the Mater Mothers Hospital Neonatal ICU; Queensland Children's Hospital Paediatric ICU; Royal Brisbane and Women's Hospital Neonatal ICU and Adult ICU; The Prince Charles Hospital Adult ICU; and the Neonatal, Paediatric and Adult ICUs at Townsville University Hospital.
Adherence to the SAFE-T Bundle will be monitored by research nurses through direct observation of nursing care. Compliance with each of the five SAFE-T Bundle elements will be recorded using yes/no measures. Compliance will be assessed during the intervention and sustainability periods. Sustainability of bundle implementation will be assessed during the one-month sustainability period following the three-month wash-out period. Nursing ICU staff will also be surveyed regarding the acceptability, appropriateness, feasibility and sustainability of the intervention.
Query!
Intervention code [1]
327580
0
Prevention
Query!
Description of the comparator or control
A sequential, multi-centre, incomplete stepped-wedge cluster randomised control trial design will be used to evaluate the SAFE-T care bundle of evidence-based clinical practices compared with standard nursing care. Every cluster ICU will provide a 4-month control period data on device-related pressure injuries. Standard nursing care will be the practices and procedures used by nurses in each separate ICU to prevent and treat device related pressure injuries.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
336805
0
Incidence of device-related pressure injury during ICU admission in the intervention group compared to control /usual care.
Query!
Assessment method [1]
336805
0
Research nurses will perform direct bedside observations of enrolled ICU patients four days per week to identify new device-related pressure injuries. On the remaining three days, including weekends, no direct bedside surveillance will occur; instead, research nurses will retrospectively review clinical records to identify any documented device-related pressure injuries. Where an injury is identified through clinical record review, research nurses will follow up on the next weekday, where possible, to confirm and classify the injury, recognising that some early injuries (e.g. Stage 1) may have resolved by the time of reassessment. The primary outcome is incidence of device-related pressure injury, defined as the number of new injuries per patient-days at risk during ICU admission. Observation time will vary between patients according to length of ICU stay. Injuries identified through either direct observation or retrospective clinical record review will be included in outcome ascertainment.
Query!
Timepoint [1]
336805
0
During the control, transition and intervention periods. Direct and indirect observations taken daily for the length of the patient admission until trial exit at day 14 or discharge or death.
Query!
Secondary outcome [1]
429723
0
Incidence rate of new ICU device-related pressure injuries per 1,000 patient-days in the intervention group compared with control/usual care
Query!
Assessment method [1]
429723
0
Research nurses will perform daily weekday (typically 4–5 days per week) direct observations of enrolled ICU patients to identify new device-related pressure injuries. On weekends, no direct bedside surveillance will occur; however, clinical records will be retrospectively reviewed by research nurses to identify any documented device-related pressure injuries. Where injuries are identified in weekend clinical records, research nurses will follow up on the next weekday (where possible) to confirm and classify the injury, recognising that some early (e.g. Stage 1) injuries may have resolved by the time of reassessment. The incidence rate will be calculated as the number of new device-related pressure injury events per 1,000 patient-days at risk during ICU admission in the intervention and control periods. Patient-days will be accrued from daily surveillance and clinical records, and all confirmed new injuries will be included in the numerator
Query!
Timepoint [1]
429723
0
During the control, transition and intervention periods. Direct and indirect observations taken daily for the length of the patient admission until trial exit at day 14 or discharge or death.
Query!
Secondary outcome [2]
429725
0
Time to new ICU device-related pressure injury development in the intervention group compared to control /usual care.
Query!
Assessment method [2]
429725
0
Research nurses will perform daily weekday direct observations of all enrolled ICU patients to identify new device-related pressure injuries. On weekends, clinical records will be retrospectively reviewed to identify any documented injuries, with confirmation and classification undertaken by research nurses on the next weekday where required. Time to device-related pressure injury will be calculated from ICU admission (date and time) to the first confirmed occurrence of a new device-related pressure injury
Query!
Timepoint [2]
429725
0
During the control, transition and intervention periods. Direct and indirect observations taken daily for the length of the patient admission until trial exit at day 14 or discharge or death.
Query!
Secondary outcome [3]
429726
0
Number of new ICU device related pressure injuries per patient in the intervention group compared to control /usual care.
Query!
Assessment method [3]
429726
0
Research nurses will perform daily weekday (typically 4–5 days per week) direct observations of enrolled ICU patients to identify new device-related pressure injuries. On weekends, no direct bedside surveillance will occur; however, clinical records will be retrospectively reviewed by research nurses to identify any documented device-related pressure injuries. Where injuries are identified in weekend clinical records, research nurses will follow up on the next weekday (where possible) to confirm and classify the injury, recognising that some early (e.g. Stage 1) injuries may have resolved by the time of reassessment. Time to device-related pressure injury will be calculated from ICU admission (date and time) to the first confirmed occurrence of a new device-related pressure injury
Query!
Timepoint [3]
429726
0
During the control, transition and intervention periods. Direct and indirect observations taken daily for the length of the patient admission until trial exit at day 14 or discharge or death.
Query!
Secondary outcome [4]
429727
0
Translational process evaluation (80% bundle adherence)
Query!
Assessment method [4]
429727
0
Process evaluation of SAFE-T bundle adherence will be conducted using structured weekly fidelity audits combining direct observation and clinical record review. Research nurses will assess delivery and documentation of SAFE-T bundle elements in enrolled ICU patients. Some elements (e.g. device selection, sizing, and securement) will be assessed at device insertion, while others (e.g. skin assessment, repositioning, and review for removal) will be assessed as ongoing care practices. Overall adherence will be calculated as the proportion of applicable SAFE-T elements delivered during each weekly audit period.
Query!
Timepoint [4]
429727
0
Data collection will occur during all periods of the trial except for washout with weekly fidelity audits conducted throughout.
Query!
Secondary outcome [5]
429728
0
Cost effectiveness of the SAFE-T bundle care (intervention period) based on health economics analysis.
Query!
Assessment method [5]
429728
0
This is a composite measure. This will include 1) Cost of products and materials used in device-related pressure injury prevention, (data collected from Health Service Managers) 2) Staff time to perform the SAFE-T bundle care (Direct observation by the Research nurses) 3) Device-related pressure injury treatment including products and medications; staff time; surgery (direct observation and chart review by the Research nurses while patient is in the ICU). All three measures will be collected daily in the final month of the intervention period.
Query!
Timepoint [5]
429728
0
All three measures will be collected daily in the final month of the intervention period.
Query!
Secondary outcome [6]
429732
0
Proportion of patients with new ICU device-related pressure injuries during the sustainability period compared to the intervention period.
Query!
Assessment method [6]
429732
0
Research nurses will perform daily weekday (typically 4–5 days per week) direct observations of enrolled ICU patients to identify new device-related pressure injuries. On weekends, no direct bedside surveillance will occur; however, clinical records will be retrospectively reviewed by research nurses to identify any documented device-related pressure injuries. Where injuries are identified in weekend clinical records, research nurses will follow up on the next weekday (where possible) to confirm and classify the injury, recognising that some early (e.g. Stage 1) injuries may have resolved by the time of reassessment. The number of patients with at least one new ICU device-related pressure injury divided by the total number of observed patients for the sustainability and intervention periods.
Query!
Timepoint [6]
429732
0
During the intervention and sustainability periods. Direct and indirect observations taken daily for the length of the patient admission until trial exit at day 14 or discharge or death
Query!
Secondary outcome [7]
430466
0
The type/stage of new ICU device-related pressure injuries
Query!
Assessment method [7]
430466
0
The study Research nurses will directly observe all enrolled patients daily for the presence of new ICU device related pressure injuries. Classified with the European Pressure Ulcer Advisory Panel & National Pressure Injury Advisory Panel staging classification. These categories include - 1) Mucosal, 2) Deep tissue Injuries, 3) Unstageable, 4) Skin Stage I, 5) Skin Stage II, 6) Skin Stage III and 7) Skin Stage IV
Query!
Timepoint [7]
430466
0
At all patient data collection periods - Control, Transition, Intervention and Sustainability periods in the step-wedge trial. Direct and indirect observations taken daily for the length of the patient admission until trial exit at day 14 or discharge or death.
Query!
Secondary outcome [8]
430482
0
Implementation outcomes of acceptability [the perception that the SAFE-T bundle is agreeable or satisfactory]
Query!
Assessment method [8]
430482
0
Implementation outcomes of acceptability will be measured with the Acceptability of Intervention Measure (AIM) which uses a 4-item questionnaire measured on a 5-point Likert scale. This outcome measure will be sent to all nurses who tended to patients enrolled in the intervention period along with other implementation outcome measures.
Query!
Timepoint [8]
430482
0
The survey will be conducted in the sustainability period - 4th month post intervention period.
Query!
Secondary outcome [9]
430483
0
Implementation outcomes of appropriateness [the perceived fit or compatibility of the SAFE-T bundle to address device related pressure injuries]
Query!
Assessment method [9]
430483
0
Implementation outcomes of appropriateness will be measured with the Intervention Appropriateness Measure (IAM) which uses a 4-item questionnaire measured on a 5-point Likert scale. This outcome measure will be sent to all nurses who tended to patients enrolled in the intervention period along with other implementation outcome measures.
Query!
Timepoint [9]
430483
0
The survey will be conducted in the sustainability period - 4th month post intervention period.
Query!
Secondary outcome [10]
430484
0
Implementation outcomes of feasibility [the extent to which the SAFE-T bundle can be successfully used by each partner site]
Query!
Assessment method [10]
430484
0
Implementation outcomes of feasibility will be measured with the Feasibility of Intervention Measure (FIM) which uses a 4-item questionnaire measured on a 5-point Likert scale. This outcome measure will be sent to all nurses who tended to patients enrolled in the intervention period along with other implementation outcome measures.
Query!
Timepoint [10]
430484
0
The survey will be conducted in the sustainability period - 4th month post intervention period.
Query!
Secondary outcome [11]
430485
0
Implementation outcomes of sustainability [normalization of complexed interventions]
Query!
Assessment method [11]
430485
0
Implementation outcomes of sustainability will be measured with the Normalisation Measure Development questionnaire, a 23-item survey assessing the normalisation of complex healthcare interventions. This questionnaire is based on normalisation process theory (NPT), measuring the normalisation of complex healthcare interventions. This outcome measure will be sent to all nurses who tended to patients enrolled in the intervention period along with other implementation outcome measures.
Query!
Timepoint [11]
430485
0
The survey will be conducted in the sustainability period - 4th month post intervention period.
Query!
Secondary outcome [12]
430488
0
Willingness to pay to avoid device-related pressure injury (survey measure)
Query!
Assessment method [12]
430488
0
A brief, tailored questionnaire containing questions on participant demographics and a scaled amounts on the cost participants would be prepared to pay to avoid device related pressure injuries. A purposively sample will be used from three key participant groups: health service managers and decision makers; ICU clinicians; and health consumers.
Query!
Timepoint [12]
430488
0
This survey will be conducted during the control and transition periods prior to implementation of the SAFE-T bundle at each site.
Query!
Secondary outcome [13]
430489
0
Implementation barriers to SAFE-T bundle uptake (CFIR-informed determinants)
Query!
Assessment method [13]
430489
0
Implementation determinants will be assessed using a structured survey incorporating participant demographics and the pragmatic context assessment tool (pCAT) Barrier Buster items. There are 14 items scored on a 5 point Likert Barrier scale from Strongly Agree to Strongly Disagree. Survey responses will be analysed and mapped to CFIR constructs to identify key implementation barriers. Identified determinants will be used to inform the selection and tailoring of implementation strategies using the Expert Recommendations for Implementing Change (ERIC) framework
Query!
Timepoint [13]
430489
0
Survey to be completed in the Control period before the workshop.
Query!
Secondary outcome [14]
430490
0
Implementation Workshops to prioritize the recommended implementation strategies
Query!
Assessment method [14]
430490
0
Implementation strategies will be developed by mapping barriers identified in the implementation survey to the Expert Recommendations for Implementing Change (ERIC) framework prior to workshops. At least one workshop will be conducted at each participating site. During workshops, participants will review a pre-generated list of ERIC-informed strategies and prioritise those most suitable for local implementation using structured consensus processes, with workshops conducted separately at each site to enable local contextual adaptation The assessment method update is a clarification of our processes and no changes to data collection was made. The assessment method clarification was made prior to commencement of participant enrolment,
Query!
Timepoint [14]
430490
0
Workshops to be completed in the Control period
Query!
Secondary outcome [15]
430494
0
Cost effectiveness Evaluation (Composite measure)
Query!
Assessment method [15]
430494
0
A within-trial cost-effectiveness analysis will estimate the cost per device related pressure injury per patient avoided. This is a composite measure made up of the following elements 1) Prospective activity logs to calculate staff time and costs for the implementation of the intervention. Staff time associated with implementation strategies as tailored in Phase 1, for example, any training, stakeholder engagement and facilitation activities, will be collected using prospective activity logs completed by the project team. 2) SAFET bundle costing: Intervention costs will include additional consumables and ICU staff level and time spent in delivering the evidence-based SAFET bundle. This will be quantified with additional patient data collection questions on the time taken to perform the bundle by the bedside nurse. These data will be collected directly by the research nurse at each site during the final month of the intervention period. 3) Hospital resource use - Prospective data collection on ICU costs associated with device related pressure injury treatments during both control and intervention periods: Any activities that represent an escalation in care due to management and/or treatment of a device related pressure injuries (until it heals or the patient is discharged). This will include staff level and time taken for visual assessment and device replacement, specific consumables used and tests/procedures required (if any).
Query!
Timepoint [15]
430494
0
For each element of this composite measure 1) Phase 1 before the start of any ICU control period 2) Final month (6th month) of the Intervention period 3) Both control and intervention periods
Query!
Secondary outcome [16]
467590
0
Implementation facilitators to SAFE-T bundle uptake (CFIR-informed determinants)
Query!
Assessment method [16]
467590
0
Implementation determinants will be assessed using a structured survey incorporating participant demographics and the pragmatic context assessment tool (pCAT) Barrier Buster items. There are 14 items scored on a facilitator 4 point Likert scale from Strong Effect to No Effect. Survey responses will be analysed and mapped to CFIR constructs to identify key implementation facilitators. Identified determinants will be used to inform the selection and tailoring of implementation strategies using the Expert Recommendations for Implementing Change (ERIC) framework
Query!
Timepoint [16]
467590
0
Survey to be completed in the Control period before the workshop.
Query!
Eligibility
Key inclusion criteria
Admitted patients have at least one therapeutic device
Query!
Minimum age
No limit
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
Patient has not been previously enrolled in the study
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The unit of randomisation is the 'cluster' not the recruited patient. The clusters (8 ICUs) will be randomised using computer software to a unique start sequence in the stepped wedge design. Each cluster will start in the control phase and cross over to intervention conditions. Sequence generation will be conducted by the Chief Investigator statistician.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Hybrid type 2 effectiveness-implementation trial using a sequential, multi-centre, incomplete, stepped-wedge, cluster randomised trial design
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Poisson generalised linear mixed-effects models will be used to analyse the primary outcome, with appropriate models applied to secondary outcomes depending on outcome type. The primary outcome of DRPI incidence between control and intervention periods will be analysed using a Poisson mixed-effects model with patient-days of observation included as an offset to account for variation in time at risk. Models will include fixed effects for time, random cluster effects, and random cluster by time effects. The correlation structure for the random cluster by time interaction will allow two-period decay, enabling correlation within the same measurement period to differ from that in different measurement periods. Results will be presented as incidence rate ratios (IRRs) with 95% confidence intervals. Negative Binomial will be used if the data are over dispersed. Time to DRPI will also be examined using mixed effects Cox regression models with hazard ratios and 95% confidence intervals reported. Assumptions of all models will be examined using residuals. Models will be adjusted for important clinical and demographic factors. The primary analysis of all endpoints will be ‘intention-to-treat’ (ITT), with ‘per protocol’ (PP) analyses assessing the effect of protocol compliance. Protocol compliance and performance (dose response) will be assessed by considering percentage compliance (yes/no) for the five components of the bundle, with compliance categorised into groups of increasing gradients from no compliance (0%) to full compliance (100%) and included as a factor in the model. Missing values will not be imputed but will be considered through the mixed modelling approach, which assumes a missing at random mechanism. Sensitivity analyses will consider models assuming missing not at random mechanism, such as shared parameter models. Two-tailed p-values of <0.05 will be considered significant.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
1/09/2025
Query!
Actual
5/01/2026
Query!
Date of last participant enrolment
Anticipated
23/07/2027
Query!
Actual
Query!
Date of last data collection
Anticipated
23/07/2027
Query!
Actual
Query!
Sample size
Target
5017
Query!
Accrual to date
1089
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
25928
0
Royal Brisbane & Womens Hospital - Herston
Query!
Recruitment hospital [2]
25929
0
Queensland Children's Hospital - South Brisbane
Query!
Recruitment hospital [3]
25930
0
Mater Mother's Hospital - South Brisbane
Query!
Recruitment hospital [4]
25931
0
The Prince Charles Hospital - Chermside
Query!
Recruitment hospital [5]
25932
0
Townsville University Hospital - Douglas
Query!
Recruitment postcode(s) [1]
41763
0
4029 - Herston
Query!
Recruitment postcode(s) [2]
41764
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [3]
41765
0
4032 - Chermside
Query!
Recruitment postcode(s) [4]
41766
0
4814 - Douglas
Query!
Funding & Sponsors
Funding source category [1]
315081
0
Government body
Query!
Name [1]
315081
0
National Health and Medical Research Council (NHMRC)
Query!
Address [1]
315081
0
National Health and Medical Research Council GPO Box 1421 Canberra City ACT 2601
Query!
Country [1]
315081
0
Australia
Query!
Funding source category [2]
315412
0
Hospital
Query!
Name [2]
315412
0
Townsville University Hospital
Query!
Address [2]
315412
0
100 Angus Smith Dr, Douglas QLD 4814
Query!
Country [2]
315412
0
Australia
Query!
Funding source category [3]
315413
0
Hospital
Query!
Name [3]
315413
0
Royal Brisbane and Women's Hospital
Query!
Address [3]
315413
0
Butterfield St, Herston QLD 4006
Query!
Country [3]
315413
0
Australia
Query!
Funding source category [4]
315423
0
Hospital
Query!
Name [4]
315423
0
The Prince Charles Hospital
Query!
Address [4]
315423
0
627 Rode Rd, Chermside QLD 4032
Query!
Country [4]
315423
0
Australia
Query!
Primary sponsor type
University
Query!
Name
The University of Queensland
Query!
Address
University of Queensland ST LUCIA QLD 4072
Query!
Country
Australia
Query!
Secondary sponsor category [1]
317476
0
None
Query!
Name [1]
317476
0
Query!
Address [1]
317476
0
Query!
Country [1]
317476
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
314029
0
Children’s Health Queensland Hospital and Health Service Human Research Ethics Committee [EC00175]
Query!
Ethics committee address [1]
314029
0
Level 7, 62 Graham Street, South Brisbane QLD 4101
Query!
Ethics committee country [1]
314029
0
Australia
Query!
Date submitted for ethics approval [1]
314029
0
09/10/2023
Query!
Approval date [1]
314029
0
08/11/2023
Query!
Ethics approval number [1]
314029
0
62 Graham Street, South Brisbane QLD 4101
Query!
Summary
Brief summary
Therapeutic devices are essential to support the clinical care of critically ill patients, yet such devices are recognised as a potential source of harm to the skin and mucous membranes in the form of therapeutic device-related pressure injuries. The neonatal, paediatric and adult populations have distinctive anatomical, physiological and developmental factors that influence their risk for device-related pressure injury development. The project aim is to co-develop implementation strategies, and then test, evaluate and disseminate a bundle of evidence-based, cost-effective scalable practices to prevent medical device-related pressure injury in critically ill patients of all ages. Phase 1 will recruit clinical staff for surveys and workshops to develop the site-specific SAFE-T bundle. Phase 2 will evaluate the effectiveness of the bundle using a multi-centre, stepped-wedge, cluster randomised trial design comparing device-related pressure injury incidence in patients (proportion) in the control period with the intervention period. The cost-effectiveness of the SAFE-T bundle will be analysed. The hypothesis of this project will be to detect a significant reduction in device-related pressure injury across the lifespan in ICU leading to the elimination of DRPI among babies, children and adults after using the SAFE-T care bundle.
Query!
Trial website
https://nmsw.uq.edu.au/research/protecting-skin-device-harm-across-lifespan-critical-illness-defence-project
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
130174
0
Prof Amanda Ullman
Query!
Address
130174
0
School of Nursing, Midwifery and Social Work, Level 3, Chamberlain Building (35), University of Queensland, St Lucia, 4072
Query!
Country
130174
0
Australia
Query!
Phone
130174
0
+61 7 3365 2068
Query!
Fax
130174
0
Query!
Email
130174
0
[email protected]
Query!
Contact person for public queries
Name
130175
0
Amanda Ullman
Query!
Address
130175
0
School of Nursing, Midwifery and Social Work, Level 3, Chamberlain Building (35), University of Queensland, St Lucia, 4072
Query!
Country
130175
0
Australia
Query!
Phone
130175
0
+61 7 3365 2068
Query!
Fax
130175
0
Query!
Email
130175
0
[email protected]
Query!
Contact person for scientific queries
Name
130176
0
Amanda Ullman
Query!
Address
130176
0
School of Nursing, Midwifery and Social Work, Level 3, Chamberlain Building (35), University of Queensland, St Lucia, 4072
Query!
Country
130176
0
Australia
Query!
Phone
130176
0
+61 7 3365 2068
Query!
Fax
130176
0
Query!
Email
130176
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment:
Individual participant data will not be shared. The outcomes of the trial will share with the public via peer-reviewed journal publications, presentations and various guidelines.
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF